Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

Publication | Open Access

DOI Full Paper Access

103

Citations

References

2018

Year

Axel Grothey, Josep Tabernero, Dirk Arnold, Aimery de Gramont, Michel Ducreux, Peter J. O’Dwyer, Eric Van Cutsem, Ivan Bosanac, Stefanie Srock, Christoph Mancao,

Annals of Oncology

MedicineCancer ManagementPathologyColorectal CancerBiomarker-driven Maintenance TreatmentPharmacotherapyCancer TreatmentOncologyRadiation OncologyAtezolizumab Vs Fp/bevModul –Molecular Oncology